Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

Albert Adam, Massimo Cugno, Giuseppe Molinaro, Melissa Perez, Yves Lepage, Angelo Agostoni

Research output: Contribution to journalArticle

Abstract

Angio-oedema is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Angio-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and in 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0.003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.

Original languageEnglish
Pages (from-to)2088-2089
Number of pages2
JournalLancet
Volume359
Issue number9323
DOIs
Publication statusPublished - Jun 15 2002

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Edema
Bradykinin
Lysine Carboxypeptidase
CD13 Antigens
Peptidyl-Dipeptidase A
Causality
X-Pro aminopeptidase
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adam, A., Cugno, M., Molinaro, G., Perez, M., Lepage, Y., & Agostoni, A. (2002). Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet, 359(9323), 2088-2089. https://doi.org/10.1016/S0140-6736(02)08914-6

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. / Adam, Albert; Cugno, Massimo; Molinaro, Giuseppe; Perez, Melissa; Lepage, Yves; Agostoni, Angelo.

In: Lancet, Vol. 359, No. 9323, 15.06.2002, p. 2088-2089.

Research output: Contribution to journalArticle

Adam, A, Cugno, M, Molinaro, G, Perez, M, Lepage, Y & Agostoni, A 2002, 'Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors', Lancet, vol. 359, no. 9323, pp. 2088-2089. https://doi.org/10.1016/S0140-6736(02)08914-6
Adam, Albert ; Cugno, Massimo ; Molinaro, Giuseppe ; Perez, Melissa ; Lepage, Yves ; Agostoni, Angelo. / Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. In: Lancet. 2002 ; Vol. 359, No. 9323. pp. 2088-2089.
@article{f20ec7ff496e4266bfcbd16bc8385563,
title = "Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors",
abstract = "Angio-oedema is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Angio-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and in 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0.003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.",
author = "Albert Adam and Massimo Cugno and Giuseppe Molinaro and Melissa Perez and Yves Lepage and Angelo Agostoni",
year = "2002",
month = "6",
day = "15",
doi = "10.1016/S0140-6736(02)08914-6",
language = "English",
volume = "359",
pages = "2088--2089",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9323",

}

TY - JOUR

T1 - Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

AU - Adam, Albert

AU - Cugno, Massimo

AU - Molinaro, Giuseppe

AU - Perez, Melissa

AU - Lepage, Yves

AU - Agostoni, Angelo

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Angio-oedema is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Angio-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and in 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0.003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.

AB - Angio-oedema is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Angio-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and in 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0.003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0037097061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037097061&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)08914-6

DO - 10.1016/S0140-6736(02)08914-6

M3 - Article

C2 - 12086766

AN - SCOPUS:0037097061

VL - 359

SP - 2088

EP - 2089

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9323

ER -